PHGE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 09:30):

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria...

Stats
Today's Volume	2 723.00
Average Volume	2.65M
Market Cap	17.67M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.630
ATR14	$0.00700 (2.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Blum Susan	Buy	0
2024-03-16	Cystic Fibrosis Foundation	Sell	0	Common Stock, par value $0.0001 per share
2024-03-16	Cystic Fibrosis Foundation	Sell	21 635 000	Series X Preferred Stock
2024-03-16	Cystic Fibrosis Foundation	Sell	10 817 500	Warrant to purchase common stock
2024-03-16	Cystic Fibrosis Foundation	Sell	4 778 265	Warrant to purchase common stock

INSIDER POWER
-67.62
Last 91 transactions
Buy: 9 333 285 \| Sell: 39 545 482

Volume Correlation

Long: -0.09 (neutral)

Short: 0.08 (neutral)

Signal:(52.288) Neutral

Biomx Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biomx Inc Correlation - Currency/Commodity

0.11
( neutral )

0.21
( neutral )

0.00
( neutral )

-0.04
( neutral )

Biomx Inc Financials

Annual	2023
Revenue:	$-357 000
Gross Profit:	$-1.23M (343.98 %)
EPS:	$-0.510

FY	2023
Revenue:	$-357 000
Gross Profit:	$-1.23M (343.98 %)
EPS:	$-0.510

FY	2022
Revenue:	$-134 000
Gross Profit:	$-2.65M (1 980.60 %)
EPS:	$-0.950

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$1.393

Financial Reports:

No articles found.

Biomx Inc

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.